Annual Accounts Receivable
$327.79 M
+$89.82 M+37.75%
31 December 2023
Summary:
Alnylam Pharmaceuticals annual accounts receivable is currently $327.79 million, with the most recent change of +$89.82 million (+37.75%) on 31 December 2023. During the last 3 years, it has risen by +$225.37 million (+220.06%). ALNY annual accounts receivable is now at all-time high.ALNY Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$353.85 M
+$44.37 M+14.34%
30 September 2024
Summary:
Alnylam Pharmaceuticals quarterly accounts receivable is currently $353.85 million, with the most recent change of +$44.37 million (+14.34%) on 30 September 2024. Over the past year, it has increased by +$28.41 million (+8.73%). ALNY quarterly accounts receivable is now at all-time high.ALNY Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALNY Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +37.8% | +8.7% |
| 3 y3 years | +220.1% | +150.8% |
| 5 y5 years | +1647.3% | +635.5% |
ALNY Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +220.1% | at high | +150.8% |
| 5 y | 5 years | at high | +1647.3% | at high | +722.7% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Alnylam Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $353.85 M(+14.3%) |
| June 2024 | - | $309.48 M(-3.7%) |
| Mar 2024 | - | $321.38 M(-2.0%) |
| Dec 2023 | $327.79 M(+37.7%) | $327.79 M(+0.7%) |
| Sept 2023 | - | $325.44 M(+47.5%) |
| June 2023 | - | $220.63 M(+0.5%) |
| Mar 2023 | - | $219.43 M(-7.8%) |
| Dec 2022 | $237.96 M(+19.8%) | $237.96 M(+29.0%) |
| Sept 2022 | - | $184.51 M(+29.7%) |
| June 2022 | - | $142.27 M(-9.1%) |
| Mar 2022 | - | $156.53 M(-21.2%) |
| Dec 2021 | $198.57 M(+93.9%) | $198.57 M(+40.8%) |
| Sept 2021 | - | $141.06 M(-3.8%) |
| June 2021 | - | $146.59 M(+32.5%) |
| Mar 2021 | - | $110.63 M(+8.0%) |
| Dec 2020 | $102.41 M(+138.1%) | $102.41 M(+29.4%) |
| Sept 2020 | - | $79.12 M(+14.5%) |
| June 2020 | - | $69.11 M(-8.5%) |
| Mar 2020 | - | $75.57 M(+75.7%) |
| Dec 2019 | $43.01 M(+129.3%) | $43.01 M(-10.6%) |
| Sept 2019 | - | $48.11 M(+56.5%) |
| June 2019 | - | $30.74 M(-9.1%) |
| Mar 2019 | - | $33.80 M(+80.2%) |
| Dec 2018 | $18.76 M(-44.8%) | $18.76 M(+458.0%) |
| Sept 2018 | - | $3.36 M(+13.5%) |
| June 2018 | - | $2.96 M(-94.2%) |
| Mar 2018 | - | $50.77 M(+49.3%) |
| Dec 2017 | $34.00 M(+45.7%) | $34.00 M(+132.2%) |
| Sept 2017 | - | $14.64 M(-4.9%) |
| June 2017 | - | $15.40 M(-20.8%) |
| Mar 2017 | - | $19.46 M(-16.6%) |
| Dec 2016 | $23.33 M | $23.33 M(+54.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2016 | - | $15.15 M(+59.2%) |
| June 2016 | - | $9.51 M(+7.9%) |
| Mar 2016 | - | $8.81 M(+6.2%) |
| Dec 2015 | $8.30 M(-79.2%) | $8.30 M(+2.1%) |
| Sept 2015 | - | $8.13 M(-13.5%) |
| June 2015 | - | $9.40 M(-7.0%) |
| Mar 2015 | - | $10.11 M(-74.7%) |
| Dec 2014 | $39.94 M(+840.1%) | $39.94 M(>+9900.0%) |
| Sept 2014 | - | $384.00 K(+331.5%) |
| June 2014 | - | $89.00 K(-45.7%) |
| Mar 2014 | - | $164.00 K(-96.1%) |
| Dec 2013 | $4.25 M(+3984.6%) | $4.25 M(+597.5%) |
| Sept 2013 | - | $609.00 K(+32.4%) |
| June 2013 | - | $460.00 K(-17.6%) |
| Mar 2013 | - | $558.00 K(+436.5%) |
| Dec 2012 | $104.00 K(-92.9%) | $104.00 K(-92.9%) |
| Dec 2011 | $1.47 M(-57.4%) | $1.47 M(-27.6%) |
| Sept 2011 | - | $2.03 M(+55.0%) |
| June 2011 | - | $1.31 M(+13.7%) |
| Mar 2011 | - | $1.15 M(-66.7%) |
| Dec 2010 | $3.45 M(-42.9%) | $3.45 M(-42.9%) |
| Dec 2009 | $6.04 M(+57.8%) | $6.04 M(+17.8%) |
| Sept 2007 | - | $5.13 M(-8.7%) |
| June 2007 | - | $5.62 M(+27.8%) |
| Mar 2007 | - | $4.39 M(+14.7%) |
| Dec 2006 | $3.83 M(+528.7%) | $3.83 M(-21.0%) |
| Sept 2006 | - | $4.85 M(+35.0%) |
| June 2006 | - | $3.59 M(+15.2%) |
| Mar 2006 | - | $3.12 M(+411.7%) |
| Dec 2005 | $609.00 K(-29.1%) | $609.00 K(+100.3%) |
| Sept 2005 | - | $304.00 K(-55.2%) |
| June 2005 | - | $679.00 K(-21.0%) |
| Dec 2004 | $859.00 K | $859.00 K |
FAQ
- What is Alnylam Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual accounts receivable year-on-year change?
- What is Alnylam Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly accounts receivable year-on-year change?
What is Alnylam Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of ALNY is $327.79 M
What is the all time high annual accounts receivable for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual accounts receivable is $327.79 M
What is Alnylam Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, ALNY annual accounts receivable has changed by +$89.82 M (+37.75%)
What is Alnylam Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of ALNY is $353.85 M
What is the all time high quarterly accounts receivable for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly accounts receivable is $353.85 M
What is Alnylam Pharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, ALNY quarterly accounts receivable has changed by +$28.41 M (+8.73%)